JP2010535814A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535814A5
JP2010535814A5 JP2010520325A JP2010520325A JP2010535814A5 JP 2010535814 A5 JP2010535814 A5 JP 2010535814A5 JP 2010520325 A JP2010520325 A JP 2010520325A JP 2010520325 A JP2010520325 A JP 2010520325A JP 2010535814 A5 JP2010535814 A5 JP 2010535814A5
Authority
JP
Japan
Prior art keywords
motomeko
opiate
active ingredient
side effects
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010520325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535814A (ja
JP5581211B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/072632 external-priority patent/WO2009023567A1/en
Publication of JP2010535814A publication Critical patent/JP2010535814A/ja
Publication of JP2010535814A5 publication Critical patent/JP2010535814A5/ja
Application granted granted Critical
Publication of JP5581211B2 publication Critical patent/JP5581211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010520325A 2007-08-09 2008-08-08 第四級オピオイドカルボキサミド Active JP5581211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95496007P 2007-08-09 2007-08-09
US60/954,960 2007-08-09
PCT/US2008/072632 WO2009023567A1 (en) 2007-08-09 2008-08-08 Quaternary opioid carboxamides

Publications (3)

Publication Number Publication Date
JP2010535814A JP2010535814A (ja) 2010-11-25
JP2010535814A5 true JP2010535814A5 (enExample) 2011-09-22
JP5581211B2 JP5581211B2 (ja) 2014-08-27

Family

ID=39941437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520325A Active JP5581211B2 (ja) 2007-08-09 2008-08-08 第四級オピオイドカルボキサミド

Country Status (14)

Country Link
US (4) US8263807B2 (enExample)
EP (1) EP2190819B1 (enExample)
JP (1) JP5581211B2 (enExample)
KR (1) KR101519682B1 (enExample)
CN (1) CN101827819B (enExample)
AU (1) AU2008286979B2 (enExample)
BR (1) BRPI0815020A2 (enExample)
CA (1) CA2694497C (enExample)
EA (1) EA020658B1 (enExample)
ES (1) ES2586245T3 (enExample)
IL (1) IL203459A (enExample)
MX (1) MX2010001371A (enExample)
NO (1) NO341089B1 (enExample)
WO (1) WO2009023567A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010006027A (es) * 2007-11-30 2010-12-21 Purdue Pharma Lp Compuestos benzomorfano.
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
EP2506712B8 (en) 2009-12-04 2019-06-19 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
JP5964809B2 (ja) 2010-03-22 2016-08-03 レンセラール ポリテクニック インスティチュート オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体
JP5728084B2 (ja) * 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
AU2012217903A1 (en) * 2011-02-14 2013-08-15 Alkermes, Inc. Peripherially acting mu opioid antagonists
KR20130132631A (ko) * 2011-03-03 2013-12-04 카딜라 핼쓰캐어 리미티드 Ｄｐｐ-ⅳ 저해제의 신규한 염
WO2012138888A1 (en) * 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
SI2725908T1 (sl) * 2011-06-29 2017-10-30 Alkermes, Inc. Periferno delujoče opioidne spojine
AU2012324012A1 (en) * 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
SMT201800664T1 (it) 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
US20160243112A1 (en) * 2015-02-25 2016-08-25 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
CN113248435B (zh) * 2020-02-13 2024-06-04 上海翰森生物医药科技有限公司 3-甲酰胺基-4-羟基纳曲酮氘代衍生物、其制备方法及其在医药上的应用
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN115521317B (zh) * 2021-02-02 2025-07-25 山东新时代药业有限公司 一种制备纳呋拉啡中间体的方法
WO2025104754A1 (en) * 2023-11-17 2025-05-22 Msn Laboratories Private Limited, R&D Center A process for the preparation of samidorphan and its intermediates
CN118598813B (zh) * 2024-08-08 2024-10-29 山东齐都药业有限公司 L-苹果酸萨米多芬及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874217A (en) 1958-10-30 1961-08-02 Albert Boehringer Normorphine derivatives
DE2254298A1 (de) * 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
CA1315689C (en) * 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
CA2242609A1 (en) * 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
EP1206264A2 (en) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
DE60032940T2 (de) * 1999-11-29 2007-11-08 Adolor Corp. Neue verfahren und zubereitungen die opioiden und deren antagonisten enthalten
CA2426942C (en) 2000-10-31 2014-06-03 Mark P. Wentland 8-carboxamido-2,6-methano-3-benzazocines
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
MXPA05003104A (es) * 2002-09-25 2005-05-27 Euro Celtique Sa Hidromorfonas n-sustituidas y uso de las mismas.
ATE444295T1 (de) * 2002-11-08 2009-10-15 Mallinckrodt Inc Verfahren zur herstellung von quaternäre n-alkyl morphinan alkaloid salzen
DK2251330T3 (da) 2004-11-05 2012-08-06 Rensselaer Polytech Inst 4-Hydroxybenzomorphaner
JP5241484B2 (ja) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
CA2615774C (en) 2005-07-21 2014-12-09 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents

Similar Documents

Publication Publication Date Title
JP2010535814A5 (enExample)
NL300929I2 (nl) Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl
JP2011522896A5 (enExample)
JP2007527914A5 (enExample)
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2009063222A3 (en) Solid compositions
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
JP2009537554A5 (enExample)
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2008006795A3 (en) Indole compounds
WO2009032843A3 (en) Deuterated ethambutols and their use
JP2009522376A5 (enExample)
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
JP2008266291A5 (enExample)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2008144320A3 (en) Opioid and methods of making and using the same
WO2010142400A3 (de) Zusammensetzungen auf basis von chitosan-oligosacchariden
JP2012097034A5 (enExample)